-

Second Class Action Filed Against Silvergate Capital (SI): Contact Robbins LLP for Information Regarding the Class Actions Against Silvergate Capital Corporation

SAN DIEGO--(BUSINESS WIRE)--The Class: Robbins LLP informs investors that another shareholder filed a class action on behalf of investors who purchased or otherwise acquired Silvergate Capital Corporation (NYSE: SI) securities, for violations of the Securities Exchange Act of 1934. The class period for the new case concerns shares purchased between November 9, 2021 and January 5, 2023. Silvergate is a digital currency company. Its platform, the Silvergate Exchange Network (“SEN”), provides payments, lending, and funding solutions for an expanding class of digital currency companies and investors. Silvergate is also the parent company of Silvergate Bank, which provides financial services that include commercial banking, commercial and residential real estate lending, mortgage warehouse lending, and commercial business lending.

What Now: Similarly situated shareholders may be eligible to participate in the class action against Silvergate. Shareholders who want to act as lead plaintiff for the class must file their papers by February 6, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case About: Silvergate Capital Corporation (SI) Made False and Misleading Statements Regarding its Business Prospects

According to the complaint, on November 15, 2022, Marcus Aurelius Research tweeted that “Recently subpoenaed Silvergate bank records reveal $425 million in transfers from $SI crypto bank accounts to South American money launderers. Affadavit from investigation into crypto crime ring linked to smugglers/drug traffickers.” On this news, the Company’s Class A common stock price fell $6.13, or 17%, to close at $29.36 per share on November 15, 2022.

Then, on November 17, 2022, The Bear Cave newsletter released an article about several companies with potential exposure to recently collapsed cryptocurrency exchange FTX, including Silvergate. The article highlighted the connection linking Silvergate to a money laundering operation that transferred $425 million off cryptocurrency trading platforms. On this news, the Company’s Class A common stock price fell $3.00, or 10.7%, to close at $24.90 per share on November 18, 2022.

On January 5, 2023, Silvergate issued a press release disclosing that total deposits from digital asset customers had declined to $3.8 billion as of December 31, 2022, compared to $11.9 billion as of September 30, 2022, a decline of roughly 68%. On this news, the Company’s Class A common stock fell more than $9.00 per share, from a closing price of $21.95 on January 4, 2023, to $12.57 on January 5, 2023, a drop of 42.73%.

Accordingly, during the class period, defendants failed to disclose to investors: (1) that the Company’s platform lacked sufficient controls and procedures to detect instances of money laundering; (2) that Silvergate’s customers had engaged in money laundering in amounts exceeding $425 million; and (3) that, as a result of the foregoing, the Company was reasonably likely to receive regulatory scrutiny and face damages, including penalties and reputational harm.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Silvergate Capital Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:SI

Release Summary
Silvergate Capital Corporation (SI) Made False and Misleading Statements Regarding its Business Prospects
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Stockholder Alert: Robbins LLP Informs Investors of the Flotek Industries, Inc. (FTK) Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Flotek Industries, Inc. (NYSE: FTK) securities between August 3, 2026 and August 17, 2026 (the "Class Period"). Flotek is an energy technology and services company.The complaint alleges that Flotek misled investors by failing to disclose the cancellation of its $400m Puerto Rican deal.Investors who suffered s...

Robbins LLP Encourages WSE Stockholders with Large Losses to Seek Counsel for the Securities Class Action Lawsuit Against Wise Group plc

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Wise Group plc (NASDAQ: WSE) securities between May 11, 2026 and July 23, 2026 (the "Class Period").The complaint alleges that Wise and certain of its senior executives violated the federal securities laws by making materially false and/or misleading statements regarding the Company's anti-money laundering compliance, a...

Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ: SPRY) securities between March 9, 2026 and June 24, 2026 (the "Class Period"). ARS is a clinical stage biopharmaceutical company focused on the development and commercialization of neffy for needle-free intranasal delivery of epinephrine for emergency treatment of Type 1 allergic reactions, incl...
Back to Newsroom